購物車
幫助
021-54845833/15800441009
中文名稱：兔抗ADGRA2多克隆抗體
|
Background: |
Endothelial receptor which functions together with RECK to enable brain endothelial cells to selectively respond to Wnt7 signals (WNT7A or WNT7B) (PubMed:28289266, PubMed:30026314). Plays a key role in Wnt7-specific responses, such as endothelial cell sprouting and migration in the forebrain and neural tube, and establishment of the blood-brain barrier (By similarity). Acts as a Wnt7-specific coactivator of canonical Wnt signaling: required to deliver RECK-bound Wnt7 to frizzled by assembling a higher-order RECK-ADGRA2-Fzd-LRP5-LRP6 complex (PubMed:30026314). ADGRA2-tethering function does not rely on its G-protein coupled receptor (GPCR) structure but instead on its combined capacity to interact with RECK extracellularly and recruit the Dishevelled scaffolding protein intracellularly (PubMed:30026314). Binds to the glycosaminoglycans heparin, heparin sulfate, chondroitin sulfate and dermatan sulfate (PubMed:16982628). |
|
Applications: |
ELISA, IHC |
|
Name of antibody: |
ADGRA2 |
|
Immunogen: |
Synthetic peptide of human ADGRA2 |
|
Full name: |
adhesion G protein-coupled receptor A2 |
|
Synonyms: |
TEM5; GPR124 |
|
SwissProt: |
Q96PE1 |
|
ELISA Recommended dilution: |
2000-5000 |
|
IHC positive control: |
Human thyroid cancer and Human gastric cancer |
|
IHC Recommend dilution: |
50-200 |
